Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LAPTOP: Phase 1/2 Study in Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer to Assess Safety and Potential Efficacy of Dual Checkpoint Inhibition in Combination with Gemcitabine and Nab-paclitaxel Followed by Immune-chemoradiation.

NCT04247165 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT04247165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04247165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LAPTOP: Phase 1/2 Study in Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer to Assess Safety and Potential Efficacy of Dual Checkpoint Inhibition in Combination with Gemcitabine and Nab-paclitaxel Followed by Immune-chemoradiation.
Lead sponsor
Herlev Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
June 2, 2020
Completion date
December 5, 2024
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable, locally advanced or metastatic pancreatic cancer